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Conventional cardiopulmonary bypass can trigger a systemic inﬂammatory response syndrome similar to sepsis. Aetiological
factors include surgical trauma, reperfusion injury, and, most importantly, contact of the blood with the synthetic surfaces of
the heart-lung machine. Recently, a new cardiopulmonary bypass system, mini-extracorporeal circulation (MECC), has been
developed and has shown promising early results in terms of reducing this inﬂammatory response. It has no venous reservoir,
a reduced priming volume, and less blood-synthetic interface. This review focuses on the inﬂammatory and clinical outcomes
of using MECC and compares these to conventional cardio-pulmonary bypass (CCPB). MECC has been shown to reduce
postoperative cytokines levels and other markers of inﬂammation. In addition, MECC reduces organ damage, postoperative
complications and the need for blood transfusion. MECC is a safe and viable perfusion option and in certain circumstances it
is superior to CCPB.
Copyright © 2009 Hunaid A. Vohra et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cardiopulmonary bypass (CPB) was ﬁrst utilised in 1953
to repair a large atrial septal defect in an 18-year-old
woman [1]. The equipment and techniques have undergone
signiﬁcant reﬁnement since then and conventional cardio-
pulmonary bypass (CCPB) has become the gold standard in
perfusion. CCPB is generally considered safe and the mortal-
ity rates are consistently low [2, 3]. In addition, CCPB allows
intracardiac procedures such as valve replacement to be
performed in a blood-free ﬁeld under controlled conditions.
The morbidity associated with cardiac surgery is relatively
high, however, with over a third of coronary artery bypass
grafting (CABG) procedures reporting complications [4].
Someofthesedeleteriouseﬀectsmaybedirectlyattributedto
CCPB-induced activation of inﬂammation and coagulation
pathways. In its most extreme form, CCPB can trigger a
systemic inﬂammatory response syndrome (SIRS) similar to
sepsis [4, 5]. This is in part related to the interface of blood
components, air, and artiﬁcial surfaces within the CCPB
apparatus [6, 7]. Through complex cellular and humoral
interactions, SIRS following CPB can lead to coagulopathy,
arrhythmias, endothelial dysfunction, neurological mani-
festations, and end-organ failure [5, 8, 9]. In the case of
CABG, one of the methods of potentially avoiding these
biosynthetic-mediated complications is to undertake beating
heart revascularisation (oﬀ-pump, OPCAB). However, no
signiﬁcant diﬀerence between OPCAB and CCPB has been
shown in terms of survival and incidence of cerebro-
vascular complications. Also, technical diﬃculties may result
in ineﬃcacious anastomoses with a lower graft patency
[10], and many “open-heart” procedures simply cannot be
performed “oﬀ-pump.”
In the last decade, there have been some exciting
developments in CPB design. These aim to reduce the
incidence of SIRS and its complications through limiting the
blood-air interface, decreasing the surface area of artiﬁcial
material, and optimising the surface coating of components.
Mini-extracorporealcirculation(MECC)isoneexamplethat
has shown promising clinical and inﬂammatory outcomes.
In this review, we consolidate current evidence and assess
whether MECC is a viable alternative to CCPB. Below is a
summaryofimportantpapersontheinﬂammatoryresponse
to MECC (Table 1).2 Mediators of Inﬂammation
Table 1: Summary of the important papers on the inﬂammatory response to MECC.
Author Summary
Immer et al. [11] 1,053 MECC patients included.
Reduced troponin levels in MECC.
Reduced postoperative IL-6 and SC5b-9 in MECC.
Lower levels of postoperative atrial ﬁbrillation in MECC.
Earlier extubation and shorter ICU stay with MECC.
Van Boven et al. [12] 184 participants.
Reduced need for transfusion in MECC.
Lower levels of MDA, allantoin/urate ratio in MECC.
Van Boven et al. [13] 20 participants.
Lower levels of CC16 in MECC.
Prasser et al. [14] 20 participants.
No diﬀerence in liver function tests or indocyanine green metabolism between MECC and
CECC groups.
Remadi et al. [15] 400 participants.
Higher CRP levels in the CECC group at 24 and 48 hours.
Greater haemoglobin/haematocrit in MECC.
Reduced need for transfusion in MECC.
Lower postoperative troponin levels in MECC.
Increased incidence of renal failure and haemoﬁltration with CECC.
Increased incidence of focal neurological deﬁcits with CECC.
No diﬀerence in length of intubation/ICU stay.
Fromes et al. [16] 60 participants.
Reduced IL-6, TNF-α, and neutrophil elastase in MECC.
No diﬀerence in IL-1β or β-thromboglobulin between MECC and CECC.
Higher levels of S100B in the CECC group.
Ohato et al. [17] 30 participants.
Lower neutrophil elastase and IL-8 in MECC.
No diﬀerence in white cell count, CRP, or IL-6 between MECC and CECC.
Reduced need for blood transfusion with MECC.
Beghi et al. [18] 60 participants.
No diﬀerence in white cell count, CRP, or IL-6 levels between MECC and CECC.
Mazzei et al. [19] 300 participants.
No diﬀerence in IL-6, creatine kinase, and S100 between MECC and OPCAB groups.
Wiesenack et al. [20] 970 participants.
Higher peak intraoperative lactate levels in CECC.
Greater haemoglobin levels and lower transfusion rates in MECC.
No diﬀerence in duration of intubation, ICU stay, or hospital stay between MECC and CECC.
Greater incidence of myocardial infarction, stroke, atrial ﬁbrillation, low cardiac output,
renal failure, dialysis, pneumonia, reintubation, deﬁbrillation, and rethoractomy in CECC.
Farneti et al. [21] 20 participants.
Lower postoperative monocyte count, percentage of monocyte-platelet aggregates, and
monocyte-platelet adhesion index in MECC.
Higher prothrombin fragments and thrombin-antithrombin III complexes in CECC.
No diﬀerence in IL-6, TNF-α,a n dβ-thromboglobulin levels between MECC and CECC.Mediators of Inﬂammation 3
2.The MECC System
In a CCPB circuit, deoxygenated blood is removed from
the body by venous cannulae usually inserted into the right
atrium. Any blood obscuring the operating ﬁeld may also be
cleared with cardiotomy suction or vents. CCPB is described
as “open circuit” because blood from these three sources
drains into a central venous reservoir where it can freely mix
withair.Thebloodsubsequentlypassesthroughamembrane
oxygenator to supply oxygen, a roller or centrifugal pump to
p r o v i d ea na d e q u a t ea r t e r i a lp r e s s u r e ,a n da na r t e r i a lﬁ l t e rt o
remove air bubbles. A heat exchanger allows the temperature
of the blood infused back into the body to be controlled. In
most procedures, oxygenated blood is returned to the body
via the aorta.
The MECC circuit incorporates a number of important
diﬀerences. First, the venous reservoir has been removed
making it a fully “closed” system Figure 1. As a consequence,
great care must be taken to avoid air entering the venous
cannulae. The lack of a venous reservoir also means that
blood is not readily available to infuse, hence suction devices
are not incorporated. However, a cardiotomy sucker can
be incorporated into the system, if required. Consequently,
blood lost into the operating ﬁeld may not be directly
reinfusedviathesystem.Greatercaremustthereforebetaken
to avoid signiﬁcant haemorrhage, making open-heart pro-
cedures requiring the venting of blood diﬃcult to perform
with MECC. Despite this, some circuits have been adapted to
incorporateasuctiondevicewhichisonlyactivatedondirect
contact with liquid (optoelectrical suction). This “semi-
closed” circuit has expanded the range of uses for MECC.
Other centres use an independent suction device attached
to a cell-saver, with postoperative autotransfusion of the
scavenged erythrocytes.
Another signiﬁcant advantage of MECC is in the reduc-
tion of priming volume provided by the use of shorter
lengths of tubing (480–900ml versus 1400–1800ml in
CCPB). Less priming volume results in less haemodilution
and a subsequent reduction in the need for perioperative
blood transfusion. In addition, shorter tubing means that
there is less surface area for the blood to interact with, which
may reduce the inﬂammatory response. Heparinisation of
patients prior to CCPB is standard, but with MECC a lower
dose of heparin may be used in comparison to CCPB (150–
200IU/kg versus 300IU/kg).
3.MECCand Markersof MyocardialInjury
Damage to the myocardium during cardiac surgery is likely
tobemultifactorial.Ischaemiaandreperfusioninjuryrelated
to aortic cross-clamping as well as direct surgical trauma
have been implicated in postoperative rises in cardiac-
speciﬁc enzymes [22]. In addition, it has been hypothesised
that the CPB machine itself contributes to myocardial injury
[22]. Indeed, retransfusion of pericardial suction blood as
occurs in CCPB is deemed to be an important trigger for
inappropriate inﬂammation [23, 24]. Furthermore, damage
tothemyocardiummaybeassociatedwiththisinﬂammatory
response [25–27]. In the largest study of its kind, Immer
et al. report the results of prospective measurement of
cardiac enzymes following CABG in patients undergoing
CPBwitheitherMECCorCCPB[11].Datafromsome1,257
patients were collected (MECC: n = 931; CCPB: n = 326).
Patients were excluded if they had a preoperative troponin
rise or a perioperative myocardial infarction. Troponin I
levels, indicative of myocardial injury, were signiﬁcantly
lower in the MECC group at 6, 12, and 24 hours after
surgery. It is worth noting that the two study groups received
diﬀerent cardioplegia regimens and it is conceivable that
intraoperative myocardial protection was inadequate in the
CCPB group. In another prospective randomised study of
60 patients, Skrabal et al. showed that patients undergoing
surgery with MECC had signiﬁcantly lower levels of serum
troponin T and creatine kinase-MB postoperatively than
those who received CCPB [22]. Importantly, the two groups
in this study received the same cardioplegia regimen, which
disputes the notion that inadequate cardioprotection may
underlie the diﬀerences in cardiac enzyme levels. Thus, it
seems that MECC may be superior to CCPB in terms of
reducing the degree of myocardial injury following cardiac
surgery.
4. MECC, OxidativeStress, and
End-OrganDysfunction
The reversal of periods of ischaemia can lead to reperfusion
injury typiﬁed by the generation of reactive oxygen species,
elevation of intracellular calcium concentrations, inﬂamma-
tion,andcelldeath[28].CPBmayresultinperiodsofrelative
tissue ischaemia of the heart and of other organs, con-
tributing to organ dysfunction and even failure [29]. Raised
malondialdehyde (MDA) and an increased allantoin/urate
ratio are recognised markers of oxidative stress in surgical
patients [30, 31]. For this reason, Van Boven et al. measured
the levels of MDA and the allantoin/urate ratios of patients
undergoing surgery with both MECC and CCPB [12]. They
found reduced levels of oxidative stress amongst the MECC
patients following removal of the aortic cross-clamp and
subsequent reperfusion. The same research group has also
studiedmarkersofalveolardamagefollowingcardiacsurgery
with MECC [13]. In particular, the group looked at CC16—
a Clara cell protein which may be elevated following acute
alveolar injury—and showed reduced levels when MECC
was used instead of CCPB. The liver is another organ prone
to ischaemic injury with a reported incidence of 1.1% of
severe early ischaemic liver injury following cardiac surgery
[32].Thisischaracterisedbyelevatedlivertransaminasesand
carries a mortality of up to 65% [32]. Prasser et al. mea-
sured serum levels of alanine aminotransferase (ALT) and
excretion of indocyanine green (a nontoxic dye metabolised
solely by the liver) in 20 patients undergoing CABG and
found no signiﬁcant diﬀerences between MECC and CCPB
groups [14]. With the aforementioned incidence of acute
liver injury, it is unsurprising that this study was unable to
demonstrate any diﬀerence in liver function between the two
interventions. Further research into end-organ dysfunction
in MECC is thus warranted.4 Mediators of Inﬂammation
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Figure 1: Schematic of the miniaturised extracorporeal circuit (MECC) on the left and of conventional extracorporeal circulation (CECC)
on the right.
5. Inﬂammatory Response to MECC
CPB stimulates a systemic inﬂammatory response medi-
ated through the interaction of air, blood, and synthetic
components in the CPB apparatus. The inﬂammation is
further driven by the physical trauma of surgery and
the eﬀects of ischaemia and reperfusion [6, 33, 34]. Its
generation is regulated by the secretion of proinﬂamma-
tory cytokines and through the activation of complement
cascades [35]. Neutrophils are the predominant cell type
involved in the inﬂammatory response after CPB, with mast
cells and basophils fulﬁlling lesser roles [9]. Neutrophil
activation can occur in response to complement or as
a reaction to heparin-protamine [36]. In addition, the
ischaemia/reperfusion injury causes thrombin deposition
which through inﬂammatory cells triggers the release of
cytokines such as interleukin (IL)-1, IL-6, IL-8, and the
expression of adhesion molecules [9]. The ensuing SIRS can
signiﬁcantly derange the haemodynamic stability of patients
even for long periods after the cessation of CPB, potentially
increasing the time required on the intensive care unit (ICU)
[37]. It is postulated that MECC could lead to a reduction in
the incidence of SIRS.
Several studies have investigated the inﬂammatory
response triggered by MECC and compared it to CCPB.
Standard postoperative measures of inﬂammation include
leukocyte count and C-reactive protein (CRP). In a study of
400 patients, Remadi et al. reported signiﬁcantly higher CRP
levels in patients receiving CCPB than in those treated with
MECC at 24 and 48 hours postoperatively [15]. Fromes et al.
described the trend in monocyte levels intraoperatively and
f o ra2 4 - h o u rp e r i o da f t e r[ 16]. They demonstrated that in
both CCPB and MECC patients, the monocyte count drops
following the initiation of bypass and then increases again
postoperatively, peaking at 24 hours. This initial decline was
attributed to the dilutional eﬀect of commencing bypass and
the later rise to the mounting inﬂammatory response. The
drop in monocyte level was greater in the CCPB group,
probably as a result of greater dilution. Interestingly, the
monocyte count rose signiﬁcantly less in the MECC group
(P = .002), suggesting that a weaker inﬂammatory process
was generated. Other authors, however, have not been able
to replicate this postoperative diﬀerence in leukocyte count
[17, 18].
Cytokines are important markers of inﬂammation and
the levels of some are known to be raised following
cardiopulmonary bypass [9, 38] .S e v e r a ls t u d i e sh a v en o w
assessed the degree of cytokine response when an MECC
system is used. Fromes et al. measured the levels of IL-1β,I L -
6, and tumour necrosis factor α (TNF-α) at six time intervals
during and after cardiopulmonary bypass (up to 24 hours
postoperatively) [16] .T h e r ei sad e b a t eo v e rw h e t h e rc a r d i a c
surgeryraisesserumIL-1β,withsomestudiesreportingarise
and others not [39–41]. Indeed, Fromes et al. were unable to
detect any signiﬁcant rise in IL-1β levels in either MECC or
CCPB patients. By contrast IL-6 levels did rise signiﬁcantly,
peaking 6 hours postoperatively. Furthermore, the levels of
IL-6 were signiﬁcantly lower in MECC patients than in those
in which CCPB was used (P = .04). There was also a rise
in serum TNF-α, with MECC levels again being lower than
those seen with CCPB (P = .002). Immer et al. measured
serum IL-6 and SC5b-9 at six time points in the ﬁrst 24
hours following surgery in 60 patients undergoing CABG
[11]. SC5b-9 is a terminal complement complex that is often
raised in inﬂammation. The levels of IL-6 and SC5b-9 were
signiﬁcantly higher following surgery in the CCPB group
thanintheMECCgroup.ThisisfurtherevidencethatMECC
is less proinﬂammatory than CCPB. Some authors, however,Mediators of Inﬂammation 5
have been unable to demonstrate any signiﬁcant diﬀerence
in IL-6 levels in MECC and CCPB patients [17, 18]. Despite
this, Ohato et al. did show signiﬁcantly lower levels of IL-8 in
MECC patients on day 1 after surgery [17].
Neutrophil elastase is a serine protease that is released
during inﬂammation to aid in the destruction of foreign
material such as bacteria [42]. The level of neutrophil
elastase is known to rise after cardiopulmonary bypass, and
is thought to be a marker of activated neutrophils [43].
Lower levels of neutrophil elastase infer a less pronounced
inﬂammatory reaction. Two studies have compared the post-
operativeserumneutrophilelastaseconcentrationinpatients
treated with CCPB and MECC [16, 17]. Both showed lower
levels of neutrophil elastase in the MECC patients. This
could in part be related to the reduced production of
proinﬂammatory cytokines and the recruitment of fewer
leukocytes.
6. ClinicalOutcomes Using MECC
30-day mortality rate is a standard outcome measure in
cardiothoracic surgery. To date, the literature suggests that
MECC neither improves nor worsens early survival rates
compared to CCPB and OPCAB [11, 16, 18–20]. Some
authors have, however, reported that using MECC decreased
the duration of intubation [11] and reduced the time spent
on the ICU [11, 18] compared to CCPB, although some
groups have been unable to replicate these ﬁndings [20].
Part of this improved early outcome with MECC could
be due to a reduction in the incidence of SIRS and its
complications. Atrial ﬁbrillation (AF) is common following
cardiac surgery and can occur in over 30% of patients
who receive CCPB [44]. Immer et al. demonstrated an
11% incidence of postoperative AF in patients who received
MECC compared to 39% in CCPB participants (P<. 001).
AF is thought to be triggered by the inﬂammation associated
with cardiopulmonary bypass [5, 8, 9]. In a large study
of the clinical outcomes of MECC, Wiesenack et al. also
reported signiﬁcantly lower rates of many postoperative
complications, including myocardial infarction, low cardiac
output, AF, pneumonia, renal failure, and cerebrovascular
events [20]. Leukocyte-platelet coaggregates play an impor-
tant role in ischaemia, clotting disorders, and inﬂammation
following contact of blood with artiﬁcial surfaces [45–47].
Farneti et al. found lower levels of circulating monocyte-
platelet aggregates in MECC patients [21]. They also found
reduced prothrombin breakdown fragment levels and serum
thrombin/antithrombin III complexes in MECC, indicative
of reduced activation of the blood coagulation system. It is
via these mechanisms that MECC could also result in fewer
thromboembolic and bleeding complications compared to
CCPB.
The large priming volumes required in CCPB can
result in signiﬁcant haemodilution with low postoperative
haemoglobin and haematocrit. Perioperative blood trans-
fusions are common and are required to ensure adequate
oxygen delivery to the myocardium and other organs. The
haemodilution is much less pronounced when MECC is
used as a consequence of the lower priming volume [11, 15,
16, 18, 20]. This can lead to a reduction in the need for
blood transfusion which in itself can be proinﬂammatory.
Indeed, Remadi et al. showed that the frequency of intra-
operative blood transfusion was 6.0% in MECC patients,
but was more than doubled in CCPB at 12.8% (P<. 001)
[15]. Meanwhile Fromes et al. showed that haematocrit
dropped by 15.3% in CCPB patients compared to only
8.5% in MECC (P<. 001) [11]. Haemodilution and the
reduction in oxygen transportation may be a contributing
factor in relative tissue ischaemia and subsequent end-organ
dysfunction.
7. Discussion
This review has consolidated the current literature on a new
form of CPB, the mini-extracorporeal circulation system.
We have paid particular attention to the role that CPB
has in generating a systemic inﬂammatory response and
have outlined ways in which MECC may be superior to
CCPB. The MECC system has shown promising results
with regard to cardiac damage and end-organ dysfunction.
Many studies have also shown that markers of inﬂammation
such as CRP, leucocytes, and cytokines are lower when
MECC is used. Most importantly, MECC is associated with
a reduction in complications, particularly arrhythmias and
thromboembolic events.
There remain some important gaps in the literature
which must be addressed with future work. Many of the
studies to date have large sample sizes for their clinical anal-
yses. However, when it comes to analysing the inﬂammatory
markers, the number of patients in each arm is often small
due to the expense of undertaking these investigations. This
makes it diﬃcult to say with conﬁdence that the patients
with a deranged inﬂammatory response were the same
ones who experienced postoperative complications. Ideally, a
moderately sized randomised controlled trial would be con-
ducted in which inﬂammatory markers were measured in all
patients. This would enable direct correlations to be drawn
between raised inﬂammatory markers, a SIRS response,
complications, and outcome for each form of bypass. In
addition, more work should look at the consequences of
MECC-related inﬂammation and in particular markers of
end-organ dysfunction, including cognitive change, renal
impairment, and heart and lung injury.
However, there are limitations of the MECC system.
With CCPB, air in the venous lines can be dealt with fairly
promptly. On the other hand, the same amount of air in the
MECC system can lead to sudden cessation of the pump. For
thisreason,somesurgeonsapplyanextrapurse-stringonthe
right atrium around the venous pipe. There is a “learning
curve” associated with the use of MECC but is not a steep
one and can be easily overcome. Most of the studies to date
have only investigated the short-term clinical outcomes of
the MECC system. If more centres are to be begin using
it as standard, it would be prudent to know more about
the long-term outcomes be these favourable or not. There
is a paucity of randomised controlled trials highlighting
long-term survival, neuro-cognitive decline, and delayed
complications in this area. Despite this, MECC remains6 Mediators of Inﬂammation
a promisingalternativetoconventionalextracorporealcircu-
lation especially in terms of its inﬂammatory results.
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